Atopic Dermatitis: Clinical Refresh
|
|
- Edwin Lloyd
- 6 years ago
- Views:
Transcription
1 In this issue: Atopic Dermatitis: Clinical Refresh Asthma Zero Albuterol Refills: 200 Puffs is Enough Safety of Tricyclic Antidepressants in Older Adults Skeletal Muscle Relaxant Quantity Limits FAQ Pharmacy News is produced quarterly for contracted network clinicians and is published under Pharmacy Web pages on MyGroupHealth for Providers. Access the site on onehealthport.com or at kp.org/wa/provider. Feel free to share the newsletter with colleagues. If you would like to be notified when the newsletter is published, or for more information about the articles, contact a Kaiser Permanente Clinical Pharmacist at or e mail: goertzen.g@ghc.org. Atopic Dermatitis: Clinical Refresh By Mark Maeda, PharmD Candidate; Edited by Galen Goertzen, PharmD, BCACP Key Points: Atopic dermatitis (AD) is a chronic skin condition that is relatively common and can have a large effect on the quality of life of affected children and adults. The majority of patients with AD will respond to topical therapies such as topical steroids or calcineurin inhibitors (CNIs - tacrolimus and pimecrolimus). Two new agents have recently been released for the treatment of AD: o Crisaborole (Eucrisa TM ) is an expensive topical agent used in the treatment of mild to moderate AD in children and adults. o Dupilumab (Dupixent ) is an extremely expensive injectable medication used in the treatment of moderate to severe AD unresponsive to other agents. Background Atopic dermatitis (or eczema) is a chronic, relapsing, pruritic inflammatory skin disease that affects up to 20% of children and 3% of adults. Dry skin and severe pruritus are the cardinal signs of AD, but the clinical presentation is highly variable. Most patients have a mild course of disease that resolves prior to adulthood. However, a small subset of patients develop severe disease, with widespread lesions that can affect sleep patterns, cause emotional and physical distress, and greatly affect a patient s quality of life. First line therapies recommended for all patients include emollients, topical 1
2 corticosteroids and/or topical immunomodulators such as topical tacrolimus or pimecrolimus. The vast majority of patients will respond adequately to one of these medications. Systemic therapies, such as cyclosporine, azathioprine, mycophenolate mofetil, and methotrexate have weak evidence supporting their use in severe disease in adults. New Drug Approvals Crisaborole (Eucrisa TM ) Crisaborole is a phosphodiesterase (PDE-4) inhibitor for the treatment of mild to moderate AD. It is a topical ointment applied twice daily and approved for adults and children age 2 and over. It was compared to vehicle in two randomized controlled trials (AD 301 and AD 302) with an endpoint of reducing the Investigator s Static Global Assessment (ISGA) to 0 or 1 AND a reduction of at least two points on a 5 (0-4) point scale. The ISGA tool helps a clinician objectively determine the extent of disease by estimating the percent of body surface area affected as well as assessing the level of erythema, lichenification, edema, and other clinical markers of disease. Crisaborole showed a statistical advantage in achieving this endpoint compared to vehicle (AD 301: 32.8% vs. 25.4%, p = 0.038; AD 302: 31.4% vs. 18.0%, p < 0.001). Crisaborole appears to have an improved short term safety profile when compared to topical corticosteroids and calcineurin inhibitors based on cross trial comparisons. No direct comparisons are available. The most common adverse event and the only one seen in greater than 1% of patients was application site pain. Long term safety is unknown. Place in therapy: Crisaborole seems to be a safe and generally effective product for mild to moderate atopic dermatitis for any patient above the age of two. However, it is approximately ten times as expensive as preferred first line agents such as topical steroids and calcineurin inhibitors so it should be used only in patients who truly cannot tolerate those medications. Coverage criteria: Trial and failure of, or intolerance to a high potency topical steroid (except in sensitive areas such as face or skin folds where low potency steroids are sufficient) AND a topical calcineurin inhibitor (CNI). Dupilumab (Dupixent ) Dupilumab is a human monoclonal antibody that inhibits interleukin-4 and interleukin-13 and is approved for the treatment of moderate to severe AD in adults age 18 and over 2
3 who have not responded or are not able to take other prescription therapies. It is an injectable product given subcutaneously 300mg every 2 weeks after a 600mg loading dose. Dupilumab was shown to be effective in two 16 week double blind, randomizedcontrolled trials. The primary efficacy endpoint (reduction of ISGA score of at least 2 points or to 0 on a 0-4 scale) was reached in 36-38% of dupilumab patients as compared to 8-10% of placebo patients (p < 0.001). In a 52 week trial 36% of patients treated with dupilumab plus topical corticosteroids (TCS) reached the endpoint compared to 13% with placebo plus TCS (p < ). Conjunctivitis and injection reaction site reactions occurred more frequently in dupilumab patients compared to placebo in both trials. No drug-related deaths occurred in either trial. Place in therapy: Dupilumab appears to be a very effective agent for the treatment of moderate to severe atopic dermatitis. But since it is a new agent with a new mechanism of action, no long term safety data, and is very expensive it should only be used in patients who have severe disease refractory to other treatments. These patients should be managed by Dermatology or Allergy. Coverage criteria: Documented moderate to severe AD using a validated assessment tool (ISGA, EASI, POEM, or SCORAD) in patients who have had an adequate trial of phototherapy, high potency steroids, topical CNIs and at least one systemic therapy. Table 1. New drug approvals for the treatment of atopic dermatitis (AD) Dosage Form Indication Directions Crisaborole (Eucrisa TM ) Dupilumab (Dupixent ) Topical Ointment 2% (60 g) Mild-Moderate AD Patients 2 years of age Apply a thin layer of crisaborole twice daily to affected areas. Cost 1 tube: $600 ~$38,000 per year *GoodRx.com as of 10/4/17 Subcutaneous Injection 300 mg/2 ml (2 ml) Moderate-Severe AD Patients 18 years of age Initial dose of 600 mg (two 300 mg injections), then 300 mg given every other week. 3
4 Conclusion For the first time in 15 years we have new agents for the treatment of atopic dermatitis, a disease which can have significant effects on the quality of life of some patients. Both crisaborole and dupilumab appear to be safe and effective and will provide additional options for patients who don t respond or can t tolerate currently available medications. Dupilumab, particularly, may be able to fill a niche in treating patients with severe disease, which can be disabling to a very small subset of AD patients. Return to top of section Asthma Zero Albuterol Refills Endorsed by: Allergy & Asthma, Asthma Oversight Team, Clinical Improvement & Prevention, Pediatrics, Pharmacy, Primary Care, and Pulmonary Clinician FAQ 200 puffs is enough How many doses of medication are in a single canister of albuterol? Each albuterol inhaler contains 200 puffs. How much albuterol is needed in patients with well controlled asthma? Patients with well controlled asthma typically need to use albuterol twice a week or less. Thus, if one uses 2 puffs twice a week that translates to 16 puffs a month or 208 puffs a year. Throw in an asthma exacerbation or two a year and 2 canisters (400 puffs) are enough for well controlled asthmatics. What if my patient is using albuterol prior to exercise? Even here if they exercise all 7 days a week that s 14 puffs a week for exercise plus 4 puffs for asthma symptoms/week so 16 puffs per week. That translates into 72 puffs a month or 864 puffs per year. Thus, 5 canisters (1,000 puffs) should more than suffice even for the rare individual that works out 7 days a week. (But bear in mind, a lot of exercise induced asthma is either uncontrolled persistent asthma or it not asthma at all, e.g., dyspnea due to deconditioning as seen if BMI >30.) 4
5 What about my patient who needs extra canisters (for school, grandma s house, to keep in the gym bag, etc.)? If we take the exceptionally rare case of someone who exercises 7 days a week and pretreats every time and needs the extra inhaler, they would still only need 5 or 6 canisters per year. And this is a very rare situation. More commonly, 2-3 canisters per year would be adequate in the significant majority of cases, if their asthma is well controlled. Also note the current KPWA formulary quantity limit for albuterol allows patients to receive up to 3 canisters in 90 days before they exceed the health plan refill limit (plus 2 extra canisters per year if extra canisters are needed for different locations such as school). Why does it matter how much albuterol I prescribe to my patients? There is a substantial body of evidence that correlates overuse of albuterol with risk of ED/UC visits, admissions, and even death from asthma. If a patient is using too much albuterol they need help controlling their asthma or their asthma diagnosis needs to be reconsidered (given 30% of adult patients diagnosed with asthma do not actually have asthma). Is it really all that important to give ZERO refills for my asthma patients? In an ideal world, we could just give patients unlimited refills and rely on them to let us know when things get out of control, but we all know that isn t how things work. Limiting albuterol to zero refills is a crude but effective means to keep tabs on our asthma patients. This approach gives us a chance to intervene and help them regain control of their asthma or perhaps discover that they don t even have asthma. What if my patient can t afford to pay for controller meds? See if patients are eligible for the KPWA Medical Financial Assistance program, which covers medically necessary healthcare services, pharmacy services, and medical supplies, in patients whose household income is at or below 300% FPG (Federal Poverty Guidelines) or who have had unusually high medical expenses. Return to top of section Safety of Tricyclic Antidepressants (TCAs) in Older Adults By Beth Arnold, PharmD, BCPP Key Points: All TCAs, including nortriptyline & desipramine, are considered high risk medications in older adults. There is more evidence coming out about the safety of using TCAs in older adults. In older patients, TCAs are associated with memory problems, falls and constipation. 5
6 We are being consistent with guidelines and geriatric experts in minimizing TCA use in the older patient population. There may be individual patients where the benefits outweigh the risks or the patient has failed other alternatives. Our goal is to find the safest option for our older adults. Background In 2015, the American Geriatrics Society (AGS) updated the Beers Criteria for Potentially Inappropriate Medication Use in Older Adults. Prior to 2015, the secondary TCAs, nortriptyline & desipramine, were excluded from this list. However, in 2015, all TCAs were added to the list because they are all highly anticholinergic, sedating and can cause orthostatic hypotension. The Beers Committee rated this as a strong recommendation based upon high quality evidence. The exception is low dose doxepin ( 6 mg daily) for sleep. As a result of the Beers criteria update, NCQA added TCAs to the High Risk Medications (HRM) initiative. The TCAs now represent the largest portion of our prescribing on the HRM initiative. Evidence for Risks of TCAs in Older Adults The TCAs are included on the Beers list of drugs with strong anticholinergic properties. This list is based upon several published anticholinergic risk scales that evaluate in vitro or in vivo receptor binding. While nortriptyline and desipramine have less anticholinergic activity than other TCAs, they still have a substantial amount. There is mounting evidence that anticholinergic burden in patients over 65 years of age is linked to an increased risk of cognitive problems. In a prospective cohort study in France that followed cumulative anticholinergic use over 4 years, a 1.4 to 2-fold higher risk of cognitive decline was observed for those who continuously used anticholinergic drugs, but not for those who had discontinued use. The risk of incident dementia was also increased in continuous users compared to patients who discontinued use. In a second prospective cohort study that followed anticholinergic use over 2 years, cognitive decline was greater in patients taking anticholinergic drugs compared to those who were not. In addition, two-year mortality was also greater in patients taking anticholinergic drugs. In a third prospective cohort study with KPWA patients that followed cumulative anticholinergic use over 10 years, there was a trend for increased risk of dementia or Alzheimer s with increasing cumulative anticholinergic dose. There is also evidence that TCAs are associated with an increased risk for falls in patients over 60 years of age, which could potentially lead to fracture, cerebral hemorrhage and loss of independence. In a meta-analysis of studies, the odds ratio for one or more falls was 1.5 (95% CI ). 6
7 Safer Alternatives There are several resources available with recommendations for alternatives to TCAs. There may be individuals where the benefits of continued therapy outweigh the risks or patients have failed other alternatives. In addition, there are certain indications that have limited treatment alternative options (fibromyalgia or GI indications) or the alternatives are also on the Beers list (urology indications). The goal is to find the safest option for our older members. HRM Chart Tool: Safer Alternatives TCA Alternatives: Neuropathic pain TCA Alternatives: Migraine prophylaxis KPWA Clinical Guidelines: Sleep disorders Depression Back pain Talking points for patients In older adults, TCAs are associated with memory problems, dry mouth, falls and constipation. There is more evidence coming out about the safety of using TCAs in older adults. We are being consistent with guidelines and geriatric experts in minimizing TCA use in the older population. Our goal is to find the safest option for our older adults. Return to top of section Skeletal Muscle Relaxant Quantity Limit Frequently Asked Questions What are the quantity limits for skeletal muscle relaxants (SMRs) and who do those limits apply to? The newly established quantity limits are as follows: Cyclobenzaprine 45 tablets per 180 days Methocarbamol 60 tablets for 180 days Orphenadrine 30 tablets per 180 days Metaxalone 60 tablets per 180 days Chlorzoxazone 60 tablets per 180 days These limits apply to all members in commercial (non-medicare) plans who are age 65 and greater. 7
8 Why are these quantity limits being put in place? SMRs are indicated for the short term relief of muscle spasm associated with acute, painful musculoskeletal conditions. There is data showing that they are efficacious in the short term 2-3 weeks maximum but there is no data showing that they are effective for chronic management of any musculoskeletal conditions. SMRs have strong sedative and anticholinergic effects which can lead to serious safety concerns in elderly patients. They are considered to be medications to avoid by the American Geriatric Association and the Beers criteria. Why is there a different quantity allowed for each SMR? The quantity limit for each drug is based on allowing a 15 day supply. For cyclobenzaprine, which is given every 8 hours or three times a day a 15 day supply would be 45 tablets. Methocarbamol is usually given four times daily or every 6 hours so 60 tablets are allowed for it. How do SMRs work? The term muscle relaxant is actually a misnomer since none of these medications actually have any kind of muscle relaxing effect. Although we don t know their exact mechanism of action, their effects seem to be mediated through their strong sedative action. What are the safety concerns with SMRs in patients over the age of 65? SMRs have very strong anticholinergic and sedative effects. These adverse reactions lead to an increased risk of fall and problematic cognitive effects. A retrospective study conducted by Kaiser Permanente of Southern California found that risk of injury leading to hospitalization, emergency department visit or urgent care visit was significantly increased in patients over the age of 65 who were taking SMRs compared to those who were not. When do these quantity limits take effect? New starts on SMRs implementation date is October 1 st, 2017 Patients established on chronic SMRs implementation date is January 1 st, 2018 Can patients pay cash for these medications if they so choose? If the physician chooses to continue to prescribe the medication and the patient chooses to pay cash (instead of using their pharmacy benefit) they will be allowed to do so. We would discourage this use due to the aforementioned safety concerns but will not block this use. Cyclobenzaprine and methocarbamol are not particularly expensive. Do you need to taper patients off of chronic skeletal muscle relaxants? Generally patients taking muscle relaxants do not need to be tapered off of their medication. (Tizanidine, baclofen & carisoprodol are exceptions to that rule.) However, if a patient has been taking an SMR consistently for a long period of time a gradual decrease over a period of a couple of weeks might make the patient more comfortable and less fearful. My patient has been taking an SMR for years now and has not had any problems. Why can t they continue? As people age they process and metabolize medications differently than they did when they were younger. Some of the changes you see might be gradual and subtle and not easily attributed to medications. Also, anticholinergic effects in particular can be cumulative, meaning the longer you take them the stronger the effects they cause, particularly on memory and cognition. One of the biggest concerns with SMRs and other medications with strong anticholinergic effects is that long term use seems to be associated with an increased risk of dementia and Alzheimer s. 8
9 Why do these quantity limits only apply to patients age 65 and over? As noted above, the sedative and anticholinergic effects seen with chronic muscle relaxant use can increase fall risk as well as risk of dementia. These problems are particularly problematic in older patients. Why isn t there similar quantity limits for tizanidine and baclofen? Are they safer options for older patients? There is no evidence to support the long-term use of tizanidine and baclofen for the treatment of low back pain or other common musculoskeletal conditions. Neither of these medications are listed as high risk medications by the Beers criteria, but both also have risks associated with their use, particularly in patients greater than age 65. The evidence for use of tizanidine and baclofen are limited to the treatment of spasticity due to spinal cord injury, including multiple sclerosis. Therefore, they are NOT recommended for long term treatment of low back pain, and should not be seen as a safer option than SMRs for treatment of common musculoskeletal conditions, particularly in patients greater than age 65. For more information on treating KPWA patients with lower back pain please refer to the Back Pain guideline on the KPWA provider website. Return to top of section References: htm?source=govdelivery&utm_medium= &utm_source=govdelivery htm htm 4. rycommittee/ucm Nissen SE, Yeomans ND, Solomon DH, et al. Cardiovascular safety of celecoxib, naproxen, or ibuprofen for arthritis. N Engl J Med. 2016; 375: Doi: NEJMoa UpToDate: Atopic dermatitis (eczema): Pathogenesis, clinical manifestations, and diagnosis 7. Eucrisa [package insert]. Palo Alto, CA: Anacor Pharmaceuticals; Dupilumab [package insert]. Tarrytown, NY: Regeneron Pharmaceuticals/Sanofi-Aventis; March Paller AS, Tom WL, Lebwohl MG et al. Efficacy and safety of crisaborole ointment, a novel, nonsteroidal phosphodiesterase 4 (PDE4) inhibitor for the topical treatment of atopic dermatitis (AD) in children and adults. J Am Acad Dermatol 2016;75: Simpson EL, Bieber T, Guttman-Yassky E. et al. Two phase 3 trials of Dupilumab versus placebo in atopic dermatitis. N Engl J Med 2016;375(24): Blauvelt A, debruin-weller M, Gooderham M et al. Long term management of moderate-to-severe atopic dermatitis with Dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomized, double-blinded, placebo-controlled, phase 3 trial. Lancet 2017;389: AGS 2015 Beers Criteria Update Expert Panel. American Geriatrics Society 2015 updated Beers criteria for potentially inappropriate medication use in older adults. J Am Geriatr Soc DOI: /jgs Carriere I, Fourrier-Reglat A, et al. Drugs with anticholinergic properties, cognitive decline and dementia in an elderly general population. Arch Intern Med 2009;169(14):
10 14. Fox C, Richardson K, et al. Anticholinergic medication use and cognitive impairment in the older populations: the medical research council cognitive function and ageing study. J Am Geriatr Soc DOI: /j x 15. Gray et al. Cumulative use of strong anticholinergics and incident dementia: a prospective cohort study. JAMA Intern Med. 2015;175 (3): Leipzig RM, Cumming RG, Tinetti ME. Drugs and falls in older people: a systematic review and metaanalysis: psychotropic drugs. J Am Geriatr Soc 1999;47(1): Spence MM, Shin PJ, Lee EA, Gibbs NE. Risk of injury associated with skeletal muscle relaxant use in older adults. Ann Pharmacother 2013;47:
CENTENE PHARMACY AND THERAPEUTICS NEW DRUG REVIEW 3Q17 July August
BRAND NAME Dupixent GENERIC NAME dupilumab MANUFACTURER Regeneron DATE OF APPROVAL March 28, 2017 PRODUCT LAUNCH DATE First week of April 2017 REVIEW TYPE Review type 1 (RT1): New Drug Review Full review
More informationUnitedHealthcare Pharmacy Clinical Pharmacy Programs
UnitedHealthcare Pharmacy Clinical Pharmacy Programs Program Number 2017 P 2116-3 Program Prior Authorization/Medical Necessity Medications Dupixent (dupilumab) P&T Approval Date 1/2017, 5/2017, 7/2017
More informationThe safety and effectiveness of Dupixent in pediatric patients have not been established (1).
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.90.30 Subject: Dupixent Page: 1 of 6 Last Review Date: September 15, 2017 Dupixent Description Dupixent
More informationEucrisa. Eucrisa (crisaborole) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Eucrisa Page: 1 of 7 Last Review Date: June 22, 2018 Eucrisa Description Eucrisa (crisaborole)
More informationPNW EPC Drug Effectiveness Review Project Summary Report Atopic Dermatitis New Drug Evaluation: Dupilumab
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationEucrisa. Eucrisa (crisaborole) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.90.25 Subject: Eucrisa Page: 1 of 6 Last Review Date: September 15, 2017 Eucrisa Description Eucrisa
More informationPNW EPC Drug Effectiveness Review Project Summary Report Atopic Dermatitis New Drug Evaluation: Dupilumab
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationMedication Policy Manual. Topic: Dupixent, dupilumab Date of Origin: March 10, Committee Approval: March 10, 2017 Next Review Date: May 2018
Independent licensees of the Blue Cross and Blue Shield Association Medication Policy Manual Policy No: dru493 Topic: Dupixent, dupilumab Date of Origin: March 10, 2017 Committee Approval: March 10, 2017
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Dupixent) Reference Number: CP.HNMC.208 Effective Date: 04.11.17 Last Review Date: 11.17 Line of Business: Medicaid Medi-Cal Revision Log See Important Reminder at the end of this policy
More informationClinical Policy: Dupilumab (Dupixent) Reference Number: ERX.SPA.49 Effective Date:
Clinical Policy: (Dupixent) Reference Number: ERX.SPA.49 Effective Date: 06.01.17 Last Review Date: 02.19 Revision Log See Important Reminder at the end of this policy for important regulatory and legal
More informationDupixent (dupilumab)
Dupixent (dupilumab) Line(s) of Business: HMO; PPO; QUEST Integration Effective Date: TBD POLICY A. INDICATIONS The indications below including FDA-approved indications and compendial uses are considered
More informationThe Role of Allergen Immunotherapy and Biologicals in the Treatment of Atopic Dermatitis
The Role of Allergen Immunotherapy and Biologicals in the Treatment of Atopic Dermatitis John Oppenheimer MD Div Allergy and Immunology UMDNJ-Rutgers Potential Conflicts of Interest Consultant GSK, Teva,
More informationAtopic Dermatitis and Topical Antipsoriatics
Atopic Dermatitis and Topical Antipsoriatics Goal(s): Restrict dermatological drugs only for funded OHP diagnoses. Moderate/severe psoriasis and moderate/severe atopic dermatitis treatments are funded
More informationWYNNIS L. TOM, MD: And I m Dr. Wynnis Tom. I m Associate Professor of Dermatology and Pediatrics at the University of California, San Diego.
LEARNING OBJECTIVES At the conclusion of this activity, participants should be better able to: Assess the severity of atopic dermatitis (AD) and its impact on the patient Evaluate treatment efficacy Design
More informationTopical Doxepin Prior Authorization with Quantity Limit Program Summary
Topical Doxepin Prior Authorization with Quantity Limit Program Summary FDA APPROVED INDICATIONS DOSAGE 1-3 Agent(s) Indication(s) Dosage & Administration Doxepin 5% cream Prudoxin (doxepin) cream 5% KS_PS_Topical_Doxepin_PAQL_ProgSum_AR1018
More informationTopical Immunomodulator Step Therapy Program
Topical Immunomodulator Step Therapy Program Policy Number: 5.01.557 Last Review: 8/2017 Origination: 7/2013 Next Review: 8/2018 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) BCBSKC will provide
More informationKatee Kindler, PharmD, BCACP
Speaker Introduction Katee Kindler, PharmD, BCACP Current Practice: Clinical Pharmacy Specialist Ambulatory Care, St. Vincent Indianapolis Assistant Professor of Pharmacy Practice, Manchester University,
More informationPositioning New Treatments for Atopic Dermatitis in Our Practice Parameter
40 th Annual Pulmonary and Allergy Update Positioning New Treatments for Atopic Dermatitis in Our Practice Parameter Mark Boguniewicz, MD Professor, Division of Allergy-Immunology Department of Pediatrics
More informationBiologic Therapies for Atopic Dermatitis and Beyond
Biologic Therapies for Atopic Dermatitis and Beyond Jonathan Corren, M.D. Departments of Medicine and Pediatrics, David Geffen School of Medicine at UCLA Disclosures Genentech - research Medimmune/AZ -
More informationDupilumab and Crisaborole for Atopic Dermatitis: Effectiveness, Value, and Value-Based Price Benchmarks
Dupilumab and Crisaborole for Atopic Dermatitis: Effectiveness, Value, and Value-Based Price Benchmarks Draft Background and Scope November 7, 2016 Background: Atopic dermatitis (eczema) is a chronic/chronically-relapsing
More informationDupilumab and Crisaborole for Atopic Dermatitis: Effectiveness and Value
Dupilumab and Crisaborole for Atopic Dermatitis: Effectiveness and Value Evidence Report May 12, 2017 Prepared for Institute for Clinical and Economic Review, 2017 ICER Staff David M. Rind, MD, MSc Chief
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Topical Doxepin Page 1 of 5 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Topical Doxepin Prime Therapeutics will review Prior Authorization requests Prior Authorization
More informationUniversity Medical Center Utrecht, Utrecht, Netherlands; 2 University of Lübeck, Lübeck, Germany; 3
Dupilumab With Concomitant Topical Corticosteroids in Adult Patients With Atopic Dermatitis who are not Adequately Controlled With or are Intolerant to Cyclosporine A, or When This Treatment is Medically
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Topical Doxepin Page 1 of 6 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Topical Doxepin (For Individuals Who Purchased BlueCare/KS Solutions/EPO Products) Prime
More informationWhat s Topical About Topicals?
What s Topical About Topicals? Megha M. Tollefson, MD Associate Professor of Dermatology and Pediatrics July 29, 2017 2015 MFMER 3513105-1 Disclosures None 2015 MFMER 3513105-2 Outline Topical steroids
More informationSkeletal Muscle Relaxants Drug Class Prior Authorization Protocol
Line of Business: Medi-Cal Effective Date: June 1, 2016 Renewal Date: August 16, 2017 Skeletal Muscle Relaxants Drug Class Prior Authorization Protocol This policy has been developed through review of
More informationLead team presentation
Lead team presentation Dupilumab for treating adults with moderate to severe atopic dermatitis [ID1048] 1 st Appraisal Committee meeting Committee B Chair: Amanda Adler Lead team: Diar Fattah, Danielle
More informationAssessing the Current Treatment of Atopic Dermatitis: Unmet Needs
Transcript Details This is a transcript of a continuing medical education (CME) activity accessible on the ReachMD network. Additional media formats for the activity and full activity details (including
More informationMeasure #238 (NQF 0022): Use of High-Risk Medications in the Elderly National Quality Strategy Domain: Patient Safety
Measure #238 (NQF 0022): Use of High-Risk Medications in the Elderly National Quality Strategy Domain: Patient Safety 2017 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY MEASURE TYPE: Process DESCRIPTION:
More informationClinical Policy: Dupilumab (Dupixent) Reference Number: ERX.SPA.49 Effective Date:
Clinical Policy: (Dupixent) Reference Number: ERX.SPA.49 Effective Date: 06.01.17 Last Review Date: 02.19 Revision Log See Important Reminder at the end of this policy for important regulatory and legal
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Policy: Atopic Dermatitis and Topical Antipsoriatics Reference Number: TCHP.PHAR.18004 Effective Date: 01.01.18 Last Review Date: 10.12.18 Line of Business: Oregon Health Plan Revision Log See Important
More informationA Yardstick for Managing Patients with Atopic Dermatitis
AAIFNA 2018 Symposium A Yardstick for Managing Patients with Atopic Dermatitis Mark Boguniewicz, MD Professor, Division of Allergy-Immunology Department of Pediatrics National Jewish Health and University
More informationReduction of High Risk Medications Using A Quality Initiative Perspective
Reduction of High Risk Medications Using A Quality Initiative Perspective Richard Mueller PharmD, MBA, MS, Director of Pharmacy Dianne Hempel BSN, RN Quality Improvement Coordinator Objectives Learn what
More informationSTEP THERAPY IN MEDICARE PART D
STEP THERAPY IN MEDICARE PART D Sarkis Kavarian, PharmD Candidate 15 Preceptor Dr. Craig Stern Pro Pharma Pharmaceutical Consultants, Inc. May 1 st, 2015 Objectives Why is this important? Medicare Part
More informationAvailable Strengths. Cost per Rx 325 mg tablet - $ mg tablet - $ mg ER tablet - $ mg capsule - $ mg chewable tablet
MEDICATION COVERAGE POLICY PHARMACY AND THERAPEUTICS ADVISORY COMMITTEE POLICY Non-Opioids LAST REVIEW 5/9/2017 THERAPEUTIC CLASS Pain REVIEW HISTORY 2/16, 5/15 LOB AFFECTED Medi-Cal (MONTH/YEAR) This
More informationDUPIXENT (dupilumab) subcutaneous injection
DUPIXENT (dupilumab) subcutaneous injection Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Pharmacy
More informationRational prescribing in the older adult. Assoc Prof Craig Whitehead
Rational prescribing in the older adult Assoc Prof Craig Whitehead Introduction Physioloical ageing and frailty Medication risks in older adults Drug Burden Anticholinergic and sedative drug burden Cascade
More informationAtopic Dermatitis: Emerging therapies. Melinda Gooderham MSc MD FRCPC
Atopic Dermatitis: Emerging therapies Melinda Gooderham MSc MD FRCPC SKiN Centre for Dermatology, Peterborough Assistant Professor, Queen s University, Kingston ON Investigator, Probity Medical Research,
More informationAn Update on Topical Therapy for Atopic Dermatitis
An Update on Topical Therapy for Atopic Dermatitis Amy S. Paller, M.D. Professor and Chair of Dermatology Professor of Pediatrics Northwestern University Feinberg School of Medicine Chicago, Illinois Disclosures
More informationIs Apremilast (Otezla) Effective in Reducing Pruritus in Adults over 18 Years Old with Plaque Psoriasis?
Philadelphia College of Osteopathic Medicine DigitalCommons@PCOM PCOM Physician Assistant Studies Student Scholarship Student Dissertations, Theses and Papers 3-2017 Is Apremilast (Otezla) Effective in
More informationUPDATES IN ATOPIC DERMATITIS
UPDATES IN ATOPIC DERMATITIS Amanda Hess, MMS, PA-C President-Elect, AAPA-AAI Arizona Asthma and Allergy Institute, Scottsdale, AZ LEARNING OBJECTIVES Discuss epidemiology, risk factors, and causes of
More informationPrior Authorization with Quantity Limit Program Summary
Gocovri (amantadine) Prior Authorization with Quantity Limit Program Summary This prior authorization applies to Commercial, NetResults A series, SourceRx and Health Insurance Marketplace formularies.
More informationQuality ID #238 (NQF 0022): Use of High-Risk Medications in the Elderly National Quality Strategy Domain: Patient Safety
Quality ID #238 (NQF 0022): Use of High-Risk Medications in the Elderly National Quality Strategy Domain: Patient Safety 2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY MEASURE TYPE: Process DESCRIPTION:
More informationNovel Insights in Atopic Dermatitis: Pathways, Biomarkers, and Phenotypes for a Targeted Approach Transcript
Novel Insights in Atopic Dermatitis: Pathways, Biomarkers, and Phenotypes for a Targeted Approach Transcript Title Slide Welcome to the CME-certified program: Novel Insights in Atopic Dermatitis; Pathways,
More informationApplication for Endorsement of CQI (Clinical Audit) Activities for MOPS Credits Allocation
Application for Endorsement of CQI (Clinical Audit) Activities for MOPS Credits Allocation Below is the form you need to fill out. NAME Dianne Vicary Health Hawke s Bay DATE JUNE 2012 TITLE OF ACTIVITY
More informationDeconstructing Polypharmacy. Alan B. Douglass, M.D. Director
Deconstructing Polypharmacy Alan B. Douglass, M.D. Director Recognize this patient? Mrs. Brown- 82 years young Active Medical Problems Hypertension Hyperlipidemia Type 2 Diabetes Peripheral edema Osteoarthritis
More informationDupilumab for treating adults with moderate to severe atopic dermatitis [ID1048]
Dupilumab for treating adults with moderate to severe atopic dermatitis [ID1048] Thank you for agreeing to give us your organisation s views on this technology and its possible use in the NHS. You can
More informationAntipsychotic Medications
TRAIL: Team Review of EVIDENCE REVIEW & RECOMMENDATIONS FOR LTC Behavioural and psychological symptoms of dementia (BPSD) refer to the non-cognitive symptoms of disturbed perception, thought content, mood
More informationPharmacy Benefit Determination Policy
Policy Subject: Atopic Dermatitis Agents Policy Number: SHS PBD18 Category: Policy Type: Medical Pharmacy Department: Pharmacy Product (check all that apply): Group HMO/POS Individual HMO/POS PPO ASO s:
More informationItchy babies: Current treatment guidelines for atopic dermatitis
Itchy babies: Current treatment guidelines for atopic dermatitis Rachel Laarman, MD Helen DeVos Children s Hospital Grand Rapids, MI Photo cred: www.dermatologytimes.modernmedicine.com I have no disclosures
More informationHospice High Dollar Medications and Possible Alternatives
Hospice High Dollar Medications and Possible Alternatives Ly M. Dang, PharmD LDang@HospicePharmacySolutions.com Director of Pharmacy Operations Hospice Pharmacy Solutions Topics of Discussion Hospice Coverage
More informationDupilumab and Crisaborole for Atopic Dermatitis: Effectiveness and Value. Public Meeting May 25, 2017
Dupilumab and Crisaborole for Atopic Dermatitis: Effectiveness and Value Public Meeting May 25, 2017 Welcome and Introduction Midwest Comparative Effectiveness Public Advisory Council (CEPAC) The Institute
More information3/1/2018. Disclosures. Objectives. Clinical advisory board member- Daiichi Sankyo
Adjuvant pain medications in geriatrics Thomas B. Gregory, Pharm.D., BCPS, CPE, FASPE Clinical Pharmacy Specialist Pain Management CoxHealth Springfield, MO Disclosures Clinical advisory board member-
More informationNovan Announces Promising Clinical Results with SB414
Novan Announces Promising Clinical Results with SB414 In the recently completed Phase 1b trial for atopic dermatitis, clinical efficacy measures were highly correlated with critical and disease-relevant
More informationPharmacy E-News February 2018
In this issue: Association between initial opioid use and the likelihood of becoming a longterm opioid user The beta agonist paradox HEDIS new measure updates for 2018 Commercial pharmacy benefit updates
More informationMedication Use in Older Adults
Medication Use in Older Adults F. Michael Gloth, III, MD, AGSF, FACP, CMD Clinical Professor Department of Geriatrics, Florida State University College of Medicine Associate Professor of Medicine Division
More informationExpert Analysis of Emerging Atopic Dermatitis Therapy Studies. A CE/CME Activity
Expert Analysis of Emerging Atopic Dermatitis Therapy Studies Overview A CE/CME Activity Lawrence F. Eichenfield, MD, and Jonathan I. Silverberg, MD, PhD, MPH, provide their perspectives on the clinical
More informationTreatments for Alzheimer s Disease A Quick Guide for Patients and Caregivers
Treatments for Alzheimer s Disease A Quick Guide for Patients and Caregivers By Kelsey F. Lee, PharmD candidate 2011 Preceptor: Demetra Antimisiaris, PharmD University of Louisvlle Dept. Family Medicine
More informationWhat is atopic dermatitis?
What is atopic dermatitis? Complex inflammatory skin disorder intense pruritus cutaneous hyperreactivity immune dysregulation Chronic with exacerbations and remissions Affects all ages, but more common
More informationHeld in conjunction with AMCP Managed Care & Specialty Pharmacy Annual Meeting Jointly provided by
Jointly provided by This activity is supported by independent educational grants from Sanofi Genzyme and Regeneron Pharmaceuticals Held in conjunction with AMCP Managed Care & Specialty Pharmacy Annual
More informationThe Burden of Atopic Dermatitis: from Population to Bedside
The Burden of Atopic Dermatitis: from Population to Bedside S028 AAD Annual Meeting March 2, 2019 Research and institutional funding Sanofi Regeneron Disclosures Consultant Honoraria Sanofi Astellas Canada
More informationLawrence F. Eichenfield, M.D.
What s New in Pediatric Dermatology Lawrence F. Eichenfield, M.D. Professor of Dermatology and Pediatrics Rady Children s Hospital, San Diego University of California, San Diego Disclosure Lawrence F.
More informationClinical Review Report
CADTH COMMON DRUG REVIEW Clinical Review Report DUPILUMAB (DUPIXENT) (Sanofi-Aventis Canada Inc.) Indication: Moderate-to-severe atopic dermatitis (AD) Service Line: CADTH Common Drug Review Version: Final
More informationOpioid Use and Misuse in Older Adults. Alison Moore, MD, MPH Division of Geriatrics and Gerontology
Opioid Use and Misuse in Older Adults Alison Moore, MD, MPH Division of Geriatrics and Gerontology 1 Why do older adults use opioids? Persistent pain is experienced by approximately half of people aged
More informationIf a bad thing is happening to a patient, a drug did it until proven otherwise
Dr Vicki s First Rule of Geriatrics Deprescribing in the Elderly Victoria Braund MD, FACP, CMD Director, Division of Geriatrics NorthShore University HealthSystem Medical Director, Brandel Health & Rehab
More informationAtopic Eczema with detail on how to apply wet wraps
Atopic Eczema with detail on how to apply wet wraps Dr Carol Hlela Consultant Dermatologist Head of Unit, Department of Dermatology, Paediatrics Red Cross Children s Hospital, UCT Red Cross War Memorial
More informationLearning Objectives 10/26/2017. New Treatments in Atopic Dermatitis
New Treatments in Atopic Dermatitis Lynda C. Schneider, MD Professor of Pediatrics, Harvard Medical School Boston Children s Hospital lynda.schneider@childrens.harvard.edu Disclosures: Lynda Schneider,
More informationMeasure #238 (NQF 0022): Use of High-Risk Medications in the Elderly National Quality Strategy Domain: Patient Safety
Measure #238 (NQF 0022): Use of High-Risk Medications in the Elderly National Quality Strategy Domain: Patient Safety 2016 PHYSICIAN QUALITY REPORTING OPTIONS FOR INDIVIDUAL MEASURES REGISTRY ONLY DESCRIPTION:
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Dupixent) Reference Number: CP.PHAR.336 Effective Date: 05.01.17 Last Review Date: 02.19 Line of Business: Commercial, HIM, Medicaid Coding Implications Revision Log See Important Reminder
More informationOpioid Analgesic Treatment Worksheet
Opioid Analgesic Treatment Worksheet Aetna Better Health of Louisiana Fax: 1 844 699 2889 www.aetnabetterhealth.com/louisiana/providers/pharmacy LA Legacy Fee for Service (FFS) Medicaid Fax: 1 866 797
More informationUnderstanding Your Patient Care Opportunity Report (PCOR)
Understanding Your Patient Care Opportunity Report (PCOR) Use your January/February 208 PCOR to help improve performance on Medicare Part D Clinical Star Ratings measures. Your January/February 208 Patient
More informationOpioids in the Management of Chronic Pain: An Overview
Opioids in the Management of Chronic Pain: An Overview Appropriate treatment of chronic pain may include both pharmacologic and non-pharmacologic modalities. The Board realizes that controlled substances,
More informationFall Prevention in Hospice (A pharmacologic and nonpharmacologic approach)
Fall Prevention in Hospice (A pharmacologic and nonpharmacologic approach) Chinenye Emereole, Pharm.D. Clinical Pharmacist Hospice Pharmacy Solutions Objectives Assess and identify hospice patients who
More informationLessons Learned from the International Eczema Council (IEC)
Lessons Learned from the International Eczema Council (IEC) Amy S. Paller, MD Northwestern University Feinberg School of Medicine American Academy of Dermatology meeting F046 February 17, 2017 No conflicts
More informationTCIs are only available on prescription and are usually started by a dermatology specialist.
(TCIs) What are topical calcineurin inhibitors? Topical calcineurin inhibitors are treatments that alter the immune system and have been developed for controlling eczema. There are two types available:
More informationClass Update: Skeletal Muscle Relaxants
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationPharmacy Management Drug Policy
SUBJECT: : Nucala (mepolizumab), Cinqair (reslizumab), & Fasenra (benralizumab) POLICY NUMBER: Pharmacy-62 EFFECTIVE DATE: 12/15 LAST REVIEW DATE: 3/5/2018 If the member s subscriber contract excludes
More informationPharmacy Management Drug Policy
SUBJECT: Multiple Sclerosis, Crohn s Disease POLICY NUMBER: PHARMACY-53 EFFECTIVE DATE: 4/08 LAST REVIEW DATE: 12/18/2018 If the member s subscriber contract excludes coverage for a specific service or
More informationGeriatric Pharmacology
Geriatric Pharmacology Janice Scheufler R.Ph.,PharmD, FASCP Clinical Pharmacist Hospice of the Western Reserve Objectives List three risk factors for adverse drug events in the elderly Discuss two physiological
More informationCOMMON SKIN CONDITIONS IN PRIMARY CARE. Ibrahim M. Zayneh, MD Dermatology Private Practice, Portsmouth, Ohio
COMMON SKIN CONDITIONS IN PRIMARY CARE Ibrahim M. Zayneh, MD Dermatology Private Practice, Portsmouth, Ohio DISCLOSURE The Speaker and members of the planning committee do not have a conflict of interest
More informationIF I M NOT TREATING WITH OPIOIDS, THEN WHAT AM I SUPPOSED TO USE?
NON-OPIOID TREATMENT OPTIONS FOR CHRONIC PAIN Alison Knutson, PharmD, BCACP Medication Management Pharmacist Park Nicollet Creekside Clinic Dr. Knutson indicated no potential conflict of interest to this
More informationDupilumab (atopic dermatitis)
IQWiG Reports Commission No. A17-63 Dupilumab (atopic dermatitis) Benefit assessment according to 35a Social Code Book V 1 Extract 1 Translation of Sections 2.1 to 2.6 of the dossier assessment Dupilumab
More informationBaclofen is a GABA-agonist, although its exact mechanism of action remains uncertain. It is known to reduce release of excitatory neurotransmitters.
Muscle relaxants may be needed, including benzodiazepines such as diazepam (Valium). For increased muscle tone (spasticity) Baclofen (Lioresal?) is a useful drug. Baclofen is a GABA-agonist, although its
More informationRich Segal, R.Ph., Ph.D. Professor and Associate Dean University of Florida
Exploring Barriers to Medication Adherence and Strategies for Improving Adherence for Asthma Rich Segal, R.Ph., Ph.D. Professor and Associate Dean University of Florida Presentation Objectives Understand
More information$"% & '( ) " * +, !"##!""$ !*$-!+*" % $&
! """# # $"% & '( ')&# '( ) " * +, '( )(*!*$-!+*"!"##!""$ % $& &. / 011 12 ' 32 3 456 3. 3 0 11 32! 71 829:1 1' 3,3 12/ 2 31:181' 337)1 / 111 3 : 39.21)2 231 1 1 13' 223 333 23) 3;3 2 1 1' 11 3 31 333
More informationMeasure #238 (NQF 0022): Use of High-Risk Medications in the Elderly National Quality Strategy Domain: Patient Safety
Measure #238 (NQF 0022): Use of High-Risk Medications in the Elderly National Quality Strategy Domain: Patient Safety 2015 PHYSICIAN QUALITY REPTING OPTIONS F INDIVIDUAL MEASURES REGISTRY ONLY DESCRIPTION:
More informationGeriatric Pharmacology. Kwi Bulow, M.D. Clinical Professor of Medicine Director, Academic Geriatric Resource Center
Geriatric Pharmacology Kwi Bulow, M.D. Clinical Professor of Medicine Director, Academic Geriatric Resource Center Silver Tsunami 2010: 40 million (13%) 2030: 72 million (20%) Baby Boomers (1946-1964)
More informationMedications are Additive (Anticholinergic) Diane W. Healey, M.D. Center for Healthy Aging March 10, 2017
Medications are Additive (Anticholinergic) Diane W. Healey, M.D. Center for Healthy Aging March 10, 2017 Disclosures This speaker has indicated there are no relevant financial relationships to be disclosed.
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
CGRP Page 1 of 8 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: CGRP (calcitonin gene-related peptide) Prime Therapeutics will review Prior Authorization requests
More informationten questions you might have about tapering (and room for your own) an informational booklet for opioid pain treatment
ten questions you might have about tapering (and room for your own) an informational booklet for opioid pain treatment This booklet was created to help you learn about tapering. You probably have lots
More informationStudent Paper PHARMACY PRACTICE. Keywords: asthma, inhalers, patient education
Assessment of Asthma Inhaler Technique in Two Community Pharmacies Nicole Farabaugh, PharmD Candidate; Ashlee McMillan, PharmD, BCACP; and Gretchen Garofoli, PharmD, BCACP WVU School of Pharmacy Keywords:
More informationMarch 9, 2015 From: The Pediatric Dermatology Research Alliance (PeDRA)
Web: www.pedraresearch.org From: The Pediatric Dermatology Research Alliance (PeDRA) To: Jennifer Shepherd, Center for Drug Evaluation and Research Food and Drug Administration, 10903 New Hampshire Ave.,
More informationPain CONCERN. Medicines for long-term pain. Antidepressants
Pain CONCERN Medicines for long-term pain Antidepressants Many people living with long-term pain (also known as chronic or persistent pain) are worried about using medicines like antidepressants. They
More informationComparative efficacy of topical mometasone furoate 0.1% cream vs topical tacrolimus 0.03% ointment in the treatment of atopic dermatitis
Original Article Comparative efficacy of topical mometasone furoate 0.1% cream vs topical tacrolimus 0.03% ointment in the treatment of atopic dermatitis Md Alauddin Khan *, Lubna Khondker **, Dilshad
More informationPOLYPHARMACY IN OLDER ADULTS AND BEERS CRITERIA UPDATE
POLYPHARMACY IN OLDER ADULTS AND BEERS CRITERIA UPDATE Jeannie Kim Lee, PharmD, BCPS, CGP Clinical Pharmacy Director College of Pharmacy The University of Arizona Learning Objectives: State the risks of
More informationIf Not Opioids then LEAH EDMONDS CSHP OCTOBER 26, 2017
If Not Opioids then what LEAH EDMONDS CSHP OCTOBER 26, 2017 Disclosure Nothing to disclose Objectives Identify various non-opioid options for the treatment of chronic non cancer pain Choose appropriate
More informationPsychotropic Medication. Including Role of Gradual Dose Reductions
Psychotropic Medication Including Role of Gradual Dose Reductions What are they? The phrase psychotropic drugs is a technical term for psychiatric medicines that alter chemical levels in the brain which
More informationCOMPOUNDING PHARMACY SOLUTIONS PRESCRIPTION COMPOUNDING FOR PAIN MANAGEMENT
JANUARY 2012 COMPOUNDING PHARMACY SOLUTIONS PRESCRIPTION COMPOUNDING WWW.CPSRXS. COM We customize individual prescriptions for the specific needs of our patients. INSIDE THIS ISSUE: Osteoarthritis Pain
More informationXATMEP (methotrexate) oral solution
XATMEP (methotrexate) oral solution Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Pharmacy
More informationAtopic Dermatitis Guidelines: What s New?
Atopic Dermatitis Guidelines: What s New? Lawrence F. Eichenfield, M.D. Professor of Dermatology and Pediatrics University of California, San Diego Rady Children s Hospital, San Diego Anacor/Pfizer Genentech
More information